96 related articles for article (PubMed ID: 9675623)
1. Mibefradil pharmacokinetic and pharmacodynamic population analysis.
Welker HA; Banken L
Int J Clin Pharmacol Res; 1998; 18(2):63-71. PubMed ID: 9675623
[TBL] [Abstract][Full Text] [Related]
2. Steady-state trough plasma mibefradil concentrations and correlation to blood pressure response in hypertensive patients with chronic renal disease.
Pordy R; Woittiez A
Int J Clin Pharmacol Res; 1998; 18(3):105-8. PubMed ID: 9825266
[TBL] [Abstract][Full Text] [Related]
3. Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist.
Petrie JR; Glen SK; MacMahon M; Crome R; Meredith PA; Elliott HL; Reid JL
J Hypertens; 1995 Dec; 13(12 Pt 2):1842-6. PubMed ID: 8903664
[TBL] [Abstract][Full Text] [Related]
4. Mibefradil, a pharmacologically distinct calcium antagonist.
Ernst ME; Kelly MW
Pharmacotherapy; 1998; 18(3):463-85. PubMed ID: 9620098
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of mibefradil in hypertensive patients with varying degrees of renal insufficiency.
Welker HA; Weidekamm E; Houwing N; de Chatel R
Pharmacology; 1998 Jun; 56(6):297-307. PubMed ID: 9654216
[TBL] [Abstract][Full Text] [Related]
6. Single- and multiple-dose mibefradil pharmacokinetics in normal and hypertensive subjects.
Welker HA
J Pharm Pharmacol; 1998 Sep; 50(9):983-7. PubMed ID: 9811158
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic interaction between oral cyclosporin and mibefradil in stabilized post-renal-transplant patients.
Spoendlin M; Peters J; Welker H; Bock A; Thiel G
Nephrol Dial Transplant; 1998 Jul; 13(7):1787-91. PubMed ID: 9681729
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacokinetics of mibefradil.
Welker HA; Wiltshire H; Bullingham R
Clin Pharmacokinet; 1998 Dec; 35(6):405-23. PubMed ID: 9884814
[TBL] [Abstract][Full Text] [Related]
9. Mibefradil, a novel calcium antagonist, in elderly patients with hypertension: favorable hemodynamics and pharmacokinetics.
Bursztyn M; Kadr H; Tilvis R; Martina B; Oigman W; Talberg J; Kobrin I
Am Heart J; 1997 Aug; 134(2 Pt 1):238-47. PubMed ID: 9313603
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of nonlinear pharmacokinetics of mibefradil in chronically instrumented dogs.
Skerjanec A; Tawfik S; Tam YK
J Pharmacol Exp Ther; 1996 Aug; 278(2):817-25. PubMed ID: 8768736
[TBL] [Abstract][Full Text] [Related]
11. Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Ro 40-5967 International Study Group.
Bakx AL; van der Wall EE; Braun S; Emanuelsson H; Bruschke AV; Kobrin I
Am Heart J; 1995 Oct; 130(4):748-57. PubMed ID: 7572582
[TBL] [Abstract][Full Text] [Related]
12. Comparison of manual versus ambulatory blood pressure measurements with pharmacokinetic-pharmacodynamic modeling of antihypertensive compounds: application to moxonidine.
Trocóniz IF; de Alwis DP; Tillmann C; Callies S; Mitchell M; Schaefer HG
Clin Pharmacol Ther; 2000 Jul; 68(1):18-27. PubMed ID: 10945312
[TBL] [Abstract][Full Text] [Related]
13. Mibefradil--a new calcium-channel blocker.
Med Lett Drugs Ther; 1997 Nov; 39(1013):103-5. PubMed ID: 9391500
[No Abstract] [Full Text] [Related]
14. Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): a new generation of calcium antagonists? Mibefradil International Study Group.
Bernink PJ; Prager G; Schelling A; Kobrin I
Hypertension; 1996 Mar; 27(3 Pt 1):426-32. PubMed ID: 8698449
[TBL] [Abstract][Full Text] [Related]
15. Nonlinear pharmacokinetics of mibefradil in the dog.
Skerjanec A; Tawfik S; Tam YK
J Pharm Sci; 1996 Feb; 85(2):189-92. PubMed ID: 8683447
[TBL] [Abstract][Full Text] [Related]
16. Mibefradil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris.
Brogden RN; Markham A
Drugs; 1997 Nov; 54(5):774-93. PubMed ID: 9360062
[TBL] [Abstract][Full Text] [Related]
17. Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension.
Oparil S; Kobrin I; Abernethy DR; Levine BS; Reif MC; Shepherd AM
Am J Hypertens; 1997 Jul; 10(7 Pt 1):735-42. PubMed ID: 9234827
[TBL] [Abstract][Full Text] [Related]
18. Effects of the T-type calcium channel blockade with oral mibefradil on the electrophysiologic properties of the human heart.
Mádle A; Linhartová K; Koza J
Med Sci Monit; 2001; 7(1):74-7. PubMed ID: 11208497
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of mibefradil in subgroups of patients with chronic stable angina pectoris.
Charlon V; Kobrin I
Int J Clin Pract; 1998 Jun; 52(4):257-64. PubMed ID: 9744152
[TBL] [Abstract][Full Text] [Related]
20. Effect of the novel T-selective calcium channel antagonist mibefradil on kidney function in comparison with amlodipine.
Greven J
Arzneimittelforschung; 1998 Aug; 48(8):806-10. PubMed ID: 9748707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
